XSDR:LSE:LSE-Xtrackers MSCI Europe Health Care ESG Screened UCITS ETF 1C (GBX)

ETF | Others |

Last Closing

USD 18646

Change

-122.00 (-0.65)%

Market Cap

USD 0.24B

Volume

842.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-2.10 (-0.75%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

+12.75 (+6.43%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+2.71 (+1.88%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.04 (+0.26%)

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.20 (+1.09%)

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.30 (+0.47%)

USD 266.08B
0QZO:LSE 0QZO

+0.60 (+0.61%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.34 (+1.14%)

USD 204.07B
0QZ3:LSE Qualcomm Inc.

+1.55 (+0.90%)

USD 202.26B

ETFs Containing XSDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.58% 41% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.58% 41% F 48% F
Trailing 12 Months  
Capital Gain 7.54% 35% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.54% 35% F 42% F
Trailing 5 Years  
Capital Gain 41.57% 62% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.57% 62% D 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 8.29% 60% D- 64% D
Dividend Return 8.29% 59% D- 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.38% 83% B 91% A-
Risk Adjusted Return 129.92% 99% N/A 100% F
Market Capitalization 0.24B 63% D 36% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike